AR084277A1 - Compuestos utiles para el tratamiento del sida - Google Patents
Compuestos utiles para el tratamiento del sidaInfo
- Publication number
- AR084277A1 AR084277A1 ARP110104670A ARP110104670A AR084277A1 AR 084277 A1 AR084277 A1 AR 084277A1 AR P110104670 A ARP110104670 A AR P110104670A AR P110104670 A ARP110104670 A AR P110104670A AR 084277 A1 AR084277 A1 AR 084277A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- nra
- hydrogen atom
- nrarb
- nrac
- Prior art date
Links
- 208000030507 AIDS Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 229910003827 NRaRb Inorganic materials 0.000 abstract 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229910052801 chlorine Chemical group 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10306417A EP2465502A1 (en) | 2010-12-15 | 2010-12-15 | Compounds useful for treating AIDS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR084277A1 true AR084277A1 (es) | 2013-05-02 |
Family
ID=43755105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104670A AR084277A1 (es) | 2010-12-15 | 2011-12-14 | Compuestos utiles para el tratamiento del sida |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9061999B2 (enExample) |
| EP (2) | EP2465502A1 (enExample) |
| JP (1) | JP6049630B2 (enExample) |
| KR (1) | KR101749232B1 (enExample) |
| CN (1) | CN103415290B (enExample) |
| AR (1) | AR084277A1 (enExample) |
| AU (1) | AU2011342826B2 (enExample) |
| BR (1) | BR112013014943B1 (enExample) |
| CA (1) | CA2819317C (enExample) |
| CU (1) | CU20130080A7 (enExample) |
| DK (1) | DK2651416T3 (enExample) |
| ES (1) | ES2681539T3 (enExample) |
| HR (1) | HRP20181190T1 (enExample) |
| MX (1) | MX337258B (enExample) |
| PL (1) | PL2651416T3 (enExample) |
| PT (1) | PT2651416T (enExample) |
| RU (1) | RU2598845C2 (enExample) |
| WO (1) | WO2012080953A1 (enExample) |
| ZA (1) | ZA201303922B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX364282B (es) | 2009-06-12 | 2019-04-22 | Abivax | Compuestos útiles para tratar envejecimiento prematuro y en particular progeria. |
| US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
| EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| CN105530938B (zh) | 2013-07-05 | 2019-10-22 | Abivax公司 | 用于治疗由逆转录病毒引起的疾病的化合物 |
| EP2975034A1 (en) * | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
| EP2974729A1 (en) * | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| EP3058940A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
| EP3059236A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
| EP3059591A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | Methods for screening compounds for treating or preventing a viral infection or a virus-related condition |
| US11130736B2 (en) | 2015-08-21 | 2021-09-28 | University Of Kansas | Human TLR8-selective agonists |
| DK3429998T3 (da) | 2016-03-18 | 2021-11-22 | Prosynergia S A R L | Fremgangsmåde til fremstilling af quinolin-2-yl-phenylaminderivater og disses salte |
| KR101966351B1 (ko) * | 2016-06-08 | 2019-04-08 | 한국과학기술연구원 | 히스톤 메틸전달효소 저해용 퀴놀린 유도체 및 이의 용도 |
| CN110996983A (zh) | 2017-06-26 | 2020-04-10 | 巴斯德研究所 | 清除hiv储库并降低病毒载量的治疗 |
| WO2019186277A1 (en) | 2018-03-28 | 2019-10-03 | Institut Pasteur | Ultrasensitive hiv-1 p24 detection assay |
| EP3594206A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
| EP3594205A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
| EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
| WO2020128033A1 (en) | 2018-12-20 | 2020-06-25 | Institut Pasteur | Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells |
| EP3669874A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of cancer |
| CN109776498B (zh) * | 2019-03-13 | 2020-04-07 | 浙江永宁药业股份有限公司 | 一种西洛他唑的制备方法 |
| EP4063351A1 (en) * | 2021-03-26 | 2022-09-28 | Abivax | Preparation method of quinoline derivative compounds |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| EP4215196A1 (en) | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
| JP2025538576A (ja) * | 2022-11-25 | 2025-11-28 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | キノリンアミン系化合物の結晶型及びその調製方法 |
| WO2025027388A1 (en) | 2023-08-01 | 2025-02-06 | Abivax | Obefazimod for treatment of ulcerative colitis |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2419199A (en) * | 1945-02-09 | 1947-04-22 | Parke Davis & Co | Quinoline compounds and process of making same |
| FR2387229A1 (fr) | 1977-04-13 | 1978-11-10 | Anvar | Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
| FR2436786A1 (fr) | 1978-09-21 | 1980-04-18 | Anvar | Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments |
| JPS59501318A (ja) * | 1982-07-26 | 1984-07-26 | アメリカン ホスピタル サプライ コ−ポレ−シヨン | ヘテロアリ−ル置換アミノメチルベンゼン誘導体 |
| US4466965A (en) * | 1982-07-26 | 1984-08-21 | American Hospital Supply Corporation | Phthalazine compounds, compositions and use |
| FR2627493B1 (fr) | 1988-02-23 | 1991-10-31 | Sanofi Sa | Procede de preparation de derives d'isoquinoleine |
| FR2645861A1 (fr) | 1989-04-17 | 1990-10-19 | Inst Nat Sante Rech Med | Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida |
| JP5209832B2 (ja) | 1999-04-05 | 2013-06-12 | シティ・オブ・ホープ | 後期糖化最終生成物（ａｇｅ）形成の新規阻害剤 |
| UA75055C2 (uk) * | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| PL375552A1 (en) | 2002-05-22 | 2005-11-28 | Amgen Inc. | Vanilloid receptor ligands and their medical applications |
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| AU2003256616B2 (en) | 2002-07-19 | 2009-08-27 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs |
| FR2849474B3 (fr) | 2002-12-27 | 2004-12-03 | Olivier Jean Noel Juin | Installation de transformation de l'energie cinetique d'un fluide en energie electrique |
| WO2004078731A1 (en) * | 2003-03-06 | 2004-09-16 | 'chemical Diversity Research Institute', Ltd. | Quinoline-carboxylic acids and the derivatives thereof, a focused library |
| FR2859475A1 (fr) | 2003-09-04 | 2005-03-11 | Centre Nat Rech Scient | Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| FR2859474B1 (fr) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| EP1853265B1 (en) | 2005-01-28 | 2016-01-27 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Farnesyltransferase inhibitors for use in the treatment of laminopathies, cellular aging and atherosclerosis |
| FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
| WO2008008234A1 (en) | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
| FR2912745A1 (fr) | 2007-02-19 | 2008-08-22 | Centre Nat Rech Scient | Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant |
| CA2681481A1 (en) | 2007-03-16 | 2008-09-25 | Mount Sinai School Of Medicine | Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction |
| WO2008143440A1 (en) | 2007-05-17 | 2008-11-27 | Lg Chem, Ltd. | New anthracene derivatives and organic electronic device using the same |
| US20090069337A1 (en) | 2007-08-15 | 2009-03-12 | Memory Pharmaceuticals Corporation | 3' substituted compounds having 5-ht6 receptor affinity |
| FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
| MX364282B (es) * | 2009-06-12 | 2019-04-22 | Abivax | Compuestos útiles para tratar envejecimiento prematuro y en particular progeria. |
-
2010
- 2010-12-15 EP EP10306417A patent/EP2465502A1/en not_active Withdrawn
-
2011
- 2011-12-13 PT PT118052307T patent/PT2651416T/pt unknown
- 2011-12-13 PL PL11805230T patent/PL2651416T3/pl unknown
- 2011-12-13 EP EP11805230.7A patent/EP2651416B1/en active Active
- 2011-12-13 KR KR1020137018457A patent/KR101749232B1/ko active Active
- 2011-12-13 US US13/993,990 patent/US9061999B2/en active Active
- 2011-12-13 MX MX2013006322A patent/MX337258B/es active IP Right Grant
- 2011-12-13 JP JP2013543948A patent/JP6049630B2/ja active Active
- 2011-12-13 HR HRP20181190TT patent/HRP20181190T1/hr unknown
- 2011-12-13 CA CA2819317A patent/CA2819317C/en active Active
- 2011-12-13 WO PCT/IB2011/055643 patent/WO2012080953A1/en not_active Ceased
- 2011-12-13 DK DK11805230.7T patent/DK2651416T3/en active
- 2011-12-13 RU RU2013126947/04A patent/RU2598845C2/ru active
- 2011-12-13 ES ES11805230.7T patent/ES2681539T3/es active Active
- 2011-12-13 CN CN201180060026.XA patent/CN103415290B/zh active Active
- 2011-12-13 AU AU2011342826A patent/AU2011342826B2/en active Active
- 2011-12-13 BR BR112013014943-4A patent/BR112013014943B1/pt active IP Right Grant
- 2011-12-14 AR ARP110104670A patent/AR084277A1/es active IP Right Grant
-
2013
- 2013-05-29 ZA ZA2013/03922A patent/ZA201303922B/en unknown
- 2013-06-13 CU CUP2013000080A patent/CU20130080A7/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2651416T3 (pl) | 2018-09-28 |
| DK2651416T3 (en) | 2018-08-06 |
| MX2013006322A (es) | 2013-10-25 |
| EP2651416A1 (en) | 2013-10-23 |
| CU20130080A7 (es) | 2013-08-29 |
| HRP20181190T1 (hr) | 2019-03-08 |
| BR112013014943A8 (pt) | 2018-06-12 |
| CN103415290B (zh) | 2016-09-14 |
| RU2598845C2 (ru) | 2016-09-27 |
| KR20140041402A (ko) | 2014-04-04 |
| CA2819317C (en) | 2017-02-28 |
| JP2013545798A (ja) | 2013-12-26 |
| AU2011342826A1 (en) | 2013-07-04 |
| PT2651416T (pt) | 2018-07-30 |
| CA2819317A1 (en) | 2012-06-21 |
| MX337258B (es) | 2016-02-22 |
| RU2013126947A (ru) | 2015-01-20 |
| JP6049630B2 (ja) | 2016-12-21 |
| BR112013014943B1 (pt) | 2022-05-03 |
| US9061999B2 (en) | 2015-06-23 |
| EP2465502A1 (en) | 2012-06-20 |
| EP2651416B1 (en) | 2018-05-09 |
| BR112013014943A2 (pt) | 2016-09-13 |
| WO2012080953A1 (en) | 2012-06-21 |
| US20130267703A1 (en) | 2013-10-10 |
| ZA201303922B (en) | 2014-07-30 |
| CN103415290A (zh) | 2013-11-27 |
| KR101749232B1 (ko) | 2017-07-03 |
| AU2011342826B2 (en) | 2016-02-11 |
| ES2681539T3 (es) | 2018-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR084277A1 (es) | Compuestos utiles para el tratamiento del sida | |
| CO2019000932A2 (es) | Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica. | |
| CU24039B1 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
| AR098912A1 (es) | Inhibidores de syk | |
| ES2722048T3 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| ECSP12012292A (es) | Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos | |
| ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| AR098048A1 (es) | Inhibidores de fgfr4 | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| MX2012015120A (es) | Derivados de imidazopiridina, su procedimiento de preparación y su uso en terapeutica. | |
| CR20120410A (es) | Pirrolidina-2-carboxamidas sustituidas | |
| AR086019A1 (es) | COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS | |
| ECSP11011201A (es) | Combinaciones que comprenden metotrexato e inhibidores de dhodh | |
| CO6160326A2 (es) | Derivados de pirrolidin-2-ona como moduladores del receptor de androgeno | |
| PE20181288A1 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer | |
| CO6160307A2 (es) | Compuestos de pirazolina y su uso y composiciones farmaceuticas | |
| CU20210023A7 (es) | Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 | |
| AR086482A1 (es) | Inhibidores de aldosterona sintasa | |
| CU20160192A7 (es) | Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble | |
| AR090086A1 (es) | COMPUESTO DE 1H-INDAZOL-3-CARBOXAMIDA COMO INHIBIDORES DE LA GLUCOGENO SINTASA CINASA 3 b | |
| ES2577382T3 (es) | Nuevos derivados de tienopirimidina, procedimientos para su preparación, y sus usos terapéuticos | |
| AR083903A1 (es) | Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos | |
| CO2017009994A2 (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |